TABLE 3:

Univariate analysis investigating associations between factors and the pre-trilostane, the post-ACTH and the total owner score

Pre-trilostane cortisol (nmol/l)n=110 dogs3-hour post-trilostane cortisol (nmol/l)n=110 dogsPost-adrenocorticotrophic hormone cortisol (nmol/l)n=110 dogsTotal owner score (well dogs only)n=93 dogs
FactorCoefficientP valueCoefficientP valueCoefficientP valueCoefficientP value
Age (years)−1.430.71−2.720.29−4.550.15*−0.180.34
Dose frequency26.020.3111.270.52−13.650.53−1.110.37
Well/unwell1.800.949.460.5816.550.43N/AN/A
Weight (kg)−0.840.44−0.680.36−0.530.57−0.070.24
Dose (mg/kg)3.500.253.7700.06*4.920.05*0.080.63
Duration at current dose (months)−1.830.11*−1.840.02*−2.250.02*−0.150.01*
Total duration of therapy (months)−1.160.13*−1.270.014*−2.19<0.01*−0.090.02*
Type** (pituitary versus adrenal)41.60.1435.350.0748.920.052.900.06
Sex (compared with female entire (n=8))
 Female neutered (n=59)−82.950.02*−41.840.07*−26.000.39−0.52<0.01*
 Male entire (n=22)−91.110.01*−46.180.07*−31.250.34−628<0.01*
 Male neutered (n=21)−122.46<0.01**−71.450.01*−31.270.34−4.710.02*
Female entire versus all
 Female entire versus all92.830.01*48.870.04* 5.35<0.01*
Visit number (compared with visit 1)
 2−20.7100.37−11.280.4723.930.22−0.180.89
 3−12.2730.67−11.780.545.220.83−0.270.86
 4+−25.7440.4614.470.5537.400.21−1.830.37
  • * indicates results with P<0.2 that were considered potentially significant

  • ** indicates that because the distinction was only made in 27/67 dogs, with only 4/27 adrenal dependent, results were not carried forward to multivariable analysis and only results P<0.05 were considered significant for this factor N/A, not applicable.